Long-Term Safety, Clinical and Immunological Outcomes in Primary Membranous Nephropathy with Severe Renal Impairment Treated with Cyclophosphamide and Steroid-Based Regimen.

Ragy, Omar; Hamilton, Patrick; Pathi, Anjali; Ahmed, Adil Abdalla Mohamed; Mitra, Sandip; Kanigicherla, Durga A K

Ragy, Omar; Hamilton, Patrick; Pathi, Anjali; Ahmed, Adil Abdalla Mohamed; Mitra, Sandip; Kanigicherla, Durga A K.

Afiliación

Ragy O; Manchester Institute of Nephrology and Transplantation, Manchester, UK.
Hamilton P; Manchester Academic Health Science Centre, Research and Innovation, Manchester University NHS Foundation Trust, Manchester, UK.
Pathi A; Manchester Institute of Nephrology and Transplantation, Manchester, UK.
Ahmed AAM; Manchester Academic Health Science Centre, Research and Innovation, Manchester University NHS Foundation Trust, Manchester, UK.
Mitra S; Manchester Institute of Nephrology and Transplantation, Manchester, UK.
Kanigicherla DAK; Manchester Institute of Nephrology and Transplantation, Manchester, UK.

Glomerular Dis ; 3(1): 88-97, 2023.

Article en En | MEDLINE | ID: mdl-37113496

Palabras clave

Cyclophosphamide; PLA2R-Ab; Primary membranous nephropathy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Observational_studies / Risk_factors_studies Idioma: En Revista: Glomerular Dis Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google